| Autor: |
Valle N; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Eapen MS; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Pillai K; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Morris R; Intensive Care Unit, Shoalhaven District Memorial Hospital, Nowra, NSW 2541, Australia., Akhter J; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Mekkawy AH; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia., Morris DL; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.; Department of Surgery, St George Hospital, Sydney, NSW 2217, Australia.; St George and Sutherland Clinical School of Medicine, University of New South Wales, Sydney, NSW 2052, Australia., Valle SJ; Mucpharm Pty Ltd., Sydney, NSW 2217, Australia.; St George and Sutherland Clinical School of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.; Intensive Care Unit, St George Hospital, Sydney, NSW 2217, Australia. |
| Abstrakt: |
Mucus plugging of the respiratory tract occurs in airway diseases, including asthma, chronic obstructive pulmonary disease, and cystic fibrosis. It can cause blockage of the airways, leading to breathlessness and lung failure. Here, we used a ventilatory setup to demonstrate the effect of BromAc ® in dissolving mucus plugs in a novel ex vivo ovine obstructive lung model. Mucus simulant was filled into the trachea of freshly slaughtered ovine lungs and ventilated via an endotracheal tube (ETT) using Continuous Mandatory Ventilation. Predetermined single or repeated doses of Bromelain, Acetylcysteine (Ac), BromAc ® , and saline control were administered via an Aerogen ® vibrating nebulizer and ventilated for 30 or 60 min. Ventilatory recording of resistance, compliance, and tidal volume was conducted, and rheology pre- and post-treatment were measured. A significant decline in airway resistance ( p < 0.0001) compared to the saline control was observed when treated with Bromelain, Ac, and BromAc ® , with the latter showing a stronger mucolytic effect than single agents. The decline in resistance was also effective in shorter time points ( p < 0.05) at lower doses of the drugs. Changes in compliance, peak pressure, and tidal volume were not observed after administration of the drugs. Rheology measurements revealed that BromAc ® TM significantly reduced the viscosity of the mucin at the end of 30 min and 60 min time points ( p < 0.001) compared to the saline control. BromAc ® showed complete dissolution of the respiratory mucus simulant and improved ventilatory airflow parameters in the ex vivo ovine model. |
